Montana 2025 Regular Session

Montana House Bill HB682

Introduced
2/24/25  
Refer
2/24/25  
Engrossed
3/7/25  
Refer
3/17/25  
Enrolled
4/30/25  

Caption

Generally revise laws regarding gender transition treatment

Impact

The bill significantly impacts state healthcare laws, as it mandates that insurance contracts now also cover detransition treatment when they cover gender transition treatments. This dual coverage aspect extends to public employee and university system insurance plans, creating a broader obligation for insurers operating in Montana. The adjustment to the statute of limitations could also set a precedent for similar actions in other areas of medical treatment, particularly concerning minors, thus influencing future legislative discussions about healthcare and legal redress in sensitive cases.

Summary

House Bill 682 is aimed at revising state laws related to gender transition treatment, particularly focusing on the coverage and liability aspects surrounding minors. The bill specifies that any tort action regarding injuries resulting from gender transition treatment must be filed within a specific timeframe, allowing for two years from the time the person reaches a specified age or from when they discover the injury. Moreover, it outlines that insurance plans covering gender transition treatments must also include provisions for detransition treatment, ensuring comparable cost-sharing policies. The bill thus addresses not only the commencement and extent of legal actions but also financial safeguards for individuals undergoing these treatments.

Sentiment

The sentiment surrounding HB 682 appears to be polarized, with strong opinions on both sides of the debate. Proponents believe it reassures youth and families navigating complex healthcare decisions by providing clarity in insurance coverage. In contrast, opponents view it as potentially restrictive to access necessary treatments and may feel it undermines the healthcare choices available to minors and their families. The discussions following the bill's introduction reflect a deep societal divide regarding gender identity and state involvement in medical decisions.

Contention

Key points of contention notably arise around the implications of placing limitations on minors' medical rights and the associated liability periods for those undergoing gender transition treatment. Critics of the bill argue that setting time limits on legal actions can disadvantage minors who may not fully understand or recognize the implications of their treatment until adulthood. Furthermore, the requirement for insurers to provide complementary coverage for detransition treatment may be seen as burdensome to insurance providers, potentially leading to increased premiums or coverage restrictions.

Companion Bills

No companion bills found.

Similar Bills

MT SB99

Provide for a youth health protection act

TX HB3399

Relating to the provision of procedures and treatments for gender transitioning, gender reassignment, or gender dysphoria and the use of public money or public assistance to provide those procedures or treatments.

TX HB1686

Relating to prohibitions on the provision to certain children of procedures and treatments for gender transitioning, gender reassignment, or gender dysphoria and on the use of public money or public assistance to provide those procedures and treatments.

TX SB14

Relating to prohibitions on the provision to certain children of procedures and treatments for gender transitioning, gender reassignment, or gender dysphoria and on the use of public money or public assistance to provide those procedures and treatments.

TX SB625

Relating to prohibitions on the provision to certain children of procedures and treatments for gender transitioning, gender reassignment, or gender dysphoria and on the use of public money or public assistance to provide those procedures and treatments.

NH SB304

Creating a cause of action for medical injuries resulting from the administration or prescription of gender transition surgery, cross-sex hormones, or puberty-blocking drugs and providing protections for individuals who receive medical detransitioning.